Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy

BACKGROUND: The INMUNOSUN trial had the objective of prospectively evaluating the efficacy and safety of sunitinib as a pure second-line treatment in patients with metastatic renal cell carcinoma (mRCC) who have progressed to first-line immune checkpoint inhibitor (ICI)-based therapies. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, E., Alonso-Gordoa, T., Reig, O., Esteban, E., Castellano, D., Garcia-del-Muro, X., Mendez, M.J., García-Donas, J., González Rodríguez, M., Arranz-Arija, J.A., Lopez-Criado, P., Molina-Cerrillo, J., Mellado, B., Alvarez-Fernandez, C., De Velasco, G., Cuéllar-Rivas, M.A., Rodríguez-Alonso, R.M., Rodríguez-Moreno, J.F., Suarez-Rodriguez, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058923/
https://www.ncbi.nlm.nih.gov/pubmed/35405437
http://dx.doi.org/10.1016/j.esmoop.2022.100463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058923/
https://www.ncbi.nlm.nih.gov/pubmed/35405437
http://dx.doi.org/10.1016/j.esmoop.2022.100463

Ejemplares similares